Prognostic factor in patient with recurrent pancreatic adenocarcinoma

Langenbecks Arch Surg. 2023 Sep 2;408(1):347. doi: 10.1007/s00423-023-03073-2.

Abstract

Purpose: To elucidate prognostic factors for post-recurrence survival in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods: Patients who underwent curative-intent surgery for PDAC between January 2014 and May 2020 were identified. Among them, patients who had postoperative recurrences and received chemotherapy were retrospectively investigated. Independent prognostic factors for survival after recurrence were investigated using multivariate analyses. Eligible patients were divided into two groups according to the presence or absence of the identified prognostic factors, and survival times after recurrence were compared.

Results: Eighty-four patients with recurrent PDAC were included. Multivariate analysis showed that red blood cell (RBC) transfusion (HR, 2.80; p = 0.0051), low albumin level (HR, 1.84; p = 0.0402), and high carbohydrate antigen 19-9 (CA19-9) level at recurrence (HR, 2.11; p = 0.0258) were significant predictors of shorter survival after recurrence. The median survival times after recurrence in the transfusion and non-transfusion groups were 5.5 vs. 18.1 months (p < 0.0001), respectively; those in the low and normal albumin groups were 10.1 vs. 18.7 months (p = 0.0049), and those in the high and normal CA19-9 groups were 11.5 vs. 22.6 months (p = 0.0023), respectively.

Conclusions: RBC transfusion, low albumin, and high CA19-9 levels at recurrence negatively affected survival after recurrence in patients with PDAC.

Keywords: Blood transfusion; Carbohydrate antigen 19-9; Low albumin; Pancreatic adenocarcinoma; Recurrence.

MeSH terms

  • Adenocarcinoma* / therapy
  • Albumins
  • CA-19-9 Antigen
  • Carcinoma, Pancreatic Ductal* / surgery
  • Humans
  • Pancreatic Neoplasms* / surgery
  • Prognosis
  • Recurrence
  • Retrospective Studies

Substances

  • CA-19-9 Antigen
  • Albumins